Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
2(33%)
Results Posted
150%(3 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_3
2
33%
Ph phase_2
4
67%

Phase Distribution

0

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
4(66.7%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(2)
Terminated(2)

Detailed Status

Completed2
Terminated2
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (66.7%)
Phase 32 (33.3%)

Trials by Status

completed233%
recruiting117%
terminated233%
active_not_recruiting117%

Recent Activity

2 active trials
Showing 5 of 6
active_not_recruitingphase_3

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

NCT03682068
recruitingphase_3

Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer

NCT05764044
terminatedphase_2

A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.

NCT01752023
completedphase_2

PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)

NCT01320254
completedphase_2

Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer

NCT01194453
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03682068Phase 3

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

Active Not Recruiting
NCT05764044Phase 3

Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer

Recruiting
NCT01752023Phase 2

A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.

Terminated
NCT01320254Phase 2

PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)

Completed
NCT01194453Phase 2

Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer

Completed
NCT00509366Phase 2

Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6